StockNews.AI
MRNA
StockNews.AI
154 days

mRNA Vaccines Market Trends and Competition Analysis 2025-2030: Revenues are Projected to Nearly Double, Growing by ~$8 Billion

1. The mRNA vaccine market grows from $9.32 billion to $10.40 billion in 2025. 2. Expected CAGR of 11.86%, reaching $18.28 billion by 2030. 3. Advances in formulation techniques redefine vaccine development boundaries. 4. Emerging trends favor dynamic mRNA solutions over traditional platforms. 5. North America leads in adoption of mRNA technology in public health.

11m saved
Insight
Article

FAQ

Why Bullish?

The mRNA market expansion directly supports Moderna's growth potential, especially with innovation and regulatory advancements. Historical trends show that increased market demand correlates to stock price appreciation for leaders like Moderna.

How important is it?

The report highlights critical market trends that could lead to enhanced revenue streams for Moderna, making it highly relevant.

Why Long Term?

The forecast projects ongoing growth through 2030, indicating long-term favorable trends for Moderna as a market leader in mRNA technology.

Related Companies

PFEBNTXMRNA
Dublin, March 18, 2025 (GLOBE NEWSWIRE) -- The "mRNA Vaccines Market by Technology Type, Route of Administration, Manufacturing Process, Vaccine Classification, Application Areas, End-User, Distribution Channel - Global Forecast 2025-2030" report has been added to ResearchAndMarkets.com's offering.The mRNA Vaccines Market grew from USD 9.32 billion in 2024 to USD 10.40 billion in 2025. It is expected to continue growing at a CAGR of 11.86%, reaching USD 18.28 billion by 2030.The mRNA vaccine landscape has experienced transformative shifts that underscore the evolution of medical innovation and technological integration. In recent years, unprecedented advances in formulation techniques and delivery systems have redefined the boundaries of vaccine development. Enhanced methods in nucleoside modification, lipid nanoparticle encapsulation, and self-amplifying mRNA platforms mean that vaccines can be deployed more precisely and at greater speeds than previously imagined.These transformative shifts are not limited solely to the technology itself; the regulatory environment, industrial collaborations, and public-private partnerships have advanced in tandem with scientific breakthroughs. A reformed regulatory outlook coupled with robust funding models has helped streamline clinical trials and expedite the approval process. Emerging trends indicate a movement away from traditional vaccine platforms toward more dynamic and responsive mRNA solutions that cater to rapidly changing health scenarios.As a result, industry participants are better positioned to anticipate market needs and harness the potential of mRNA. The emphasis on scalability and adaptability is evident in the way manufacturers and innovators are rethinking production methodologies. By investing in innovative manufacturing processes and reimagining the vaccine life cycle, key players are not only responding to current challenges but are also preparing to meet future public health demands. This evolution is transforming market dynamics while setting a new standard for what is achievable with modern vaccine technology.Global Regional Insights and Market OpportunitiesThe global reach of mRNA vaccine technology offers a range of regional insights that are especially pertinent in today's connected world. In the Americas, strong investment in biotechnology research and development, coupled with robust healthcare infrastructure, has created fertile ground for mRNA innovations. North American markets, in particular, have been quick to adopt the latest vaccine technologies, leading to rapid integration into public health strategies.Europe, Middle East & Africa showcase a mixed landscape where advanced healthcare systems in parts of Europe drive market maturity, while emerging markets in the Middle East and Africa offer significant potential through rapidly evolving regulatory frameworks and government incentives. These regions demonstrate a balanced blend of established research excellence and untapped market potential.Meanwhile, the Asia-Pacific region stands out with its diverse market dynamics. The confluence of high population density, increasing bio-tech investments, and proactive government policies has fostered a thriving environment for mRNA vaccine development. The interplay between tradition and modernity in healthcare delivery, combined with improvements in regional manufacturing capacities, positions the Asia-Pacific as a vital market for future growth. These regional insights illustrate the broad geographic impact of mRNA vaccine innovation and underscore the importance of a tailored approach to market strategies in each region.Competitive LandscapeThe report delves into recent significant developments in the mRNA Vaccines Market, highlighting leading vendors and their innovative profiles. These include: Acuitas Therapeutics Inc.Alnylam Pharmaceuticals Inc.Arcturus Therapeutics Holdings Inc.AstraZeneca PLCBavarian Nordic ASBioNTech SEChongqing Zhifei Biological Products Co. Ltd.CureVac N.V.Daiichi Sankyo Company LimitedEli Lilly and CompanyEthris GmbHGlaxoSmithKline PLCInovio Pharmaceuticals Inc.Johnson & Johnson Services Inc.Merck & Co. Inc.Moderna Inc.Novartis AGPfizer Inc.Regeneron Pharmaceuticals Inc.Roche Holding AGSanofi SASinovac Biotech Ltd.Takeda Pharmaceutical Company LimitedThermo Fisher Scientific Inc.Vertex Pharmaceuticals Incorporated Strategic Recommendations for Market AdvancementIndustry leaders are encouraged to prioritize adaptive strategies and proactive investments in advanced manufacturing techniques to maintain competitive advantage. It is imperative for decision-makers to anticipate regulatory trends and invest in agile production methods, such as cell-free synthesis and in vitro transcription, to reduce time-to-market for new vaccine candidates. Strengthening public-private partnerships can facilitate innovation and accelerate the development of next-generation mRNA platforms. Collaborative ventures that bridge research institutions and industry leaders will be essential to harness the full potential of mRNA technology.Moreover, leveraging data-driven insights into market segmentation and regional dynamics can inform targeted product launch strategies. By closely monitoring end-user requirements and distribution channel efficiencies, market stakeholders can better navigate competitive pressures and ensure sustainable growth in a dynamic global landscape.Key Attributes Report AttributeDetailsNo. of Pages199Forecast Period2025-2030Estimated Market Value (USD) in 2025$10.4 BillionForecasted Market Value (USD) by 2030$18.28 BillionCompound Annual Growth Rate11.8%Regions CoveredGlobal Key Topics Covered1. Preface2. Research Methodology3. Executive Summary4. Market Overview5. Market Insights5.1. Market Dynamics5.1.1. Drivers5.1.1.1. Growing prevalence of infectious diseases and emerging viral outbreaks spur demand for mRNA vaccines5.1.1.2. Expansion of mRNA vaccine in animal health sectors is set to market potential5.1.1.3. Public and governmental support for pandemic preparedness pushes forward mRNA vaccine initiatives5.1.2. Restraints5.1.2.1. Public skepticism towards new vaccine technologies, by misinformation, could impede uptake.5.1.3. Opportunities5.1.3.1. Developing educational campaigns and public-private partnerships to promote mRNA vaccine benefits and safety5.1.3.2. Governmental and private funding to advance mRNA vaccine research and development5.1.4. Challenges5.1.4.1. Understanding the complex regulatory frameworks for mRNA vaccine approvals5.2. Market Segmentation Analysis5.2.1. Technology Type: Growing use of lipid nanoparticle platforms for their ability to deliver mRNA into cells effectively5.2.2. Distribution Channel: Adoption of hospital pharmacies for storing and timely administering mRNA vaccines5.3. Porter's Five Forces Analysis5.4. PESTLE Analysis6. mRNA Vaccines Market, by Technology Type6.1. Introduction6.2. Lipid Nanoparticle (LNP) Platforms6.3. Naked mRNA Technologies6.3.1. Peptide-Based Carriers6.3.2. Polymeric Nanoparticles6.4. Nucleoside-Modified mRNA Technologies6.5. Self-Amplifying mRNA Platforms7. mRNA Vaccines Market, by Route of Administration7.1. Introduction7.2. Inhalable mRNA Vaccines7.3. Injectable mRNA Vaccines7.4. Oral Delivery System8. mRNA Vaccines Market, by Manufacturing Process8.1. Introduction8.2. Cell-Free Synthesis8.3. In Vitro Transcription9. mRNA Vaccines Market, by Vaccine Classification9.1. Introduction9.2. Preventive Vaccines9.3. Therapeutic Vaccines10. mRNA Vaccines Market, by Application Areas10.1. Introduction10.2. Cardiovascular Disorders10.3. Genetic Disorders10.3.1. Cystic Fibrosis Treatments10.3.2. Sickle Cell Disease mRNA Approaches10.4. Infectious Diseases10.4.1. COVID-19 Vaccines10.4.2. Influenza mRNA Vaccines10.5. Oncology11. mRNA Vaccines Market, by End-User11.1. Introduction11.2. Biotechnology Firms11.3. Contract Research Organizations11.4. Pharmaceutical Companies11.5. Research Institutes12. mRNA Vaccines Market, by Distribution Channel12.1. Introduction12.2. Hospital Pharmacies12.3. Retail Pharmacies13. Americas mRNA Vaccines Market13.1. Introduction13.2. Argentina13.3. Brazil13.4. Canada13.5. Mexico13.6. United States14. Asia-Pacific mRNA Vaccines Market14.1. Introduction14.2. Australia14.3. China14.4. India14.5. Indonesia14.6. Japan14.7. Malaysia14.8. Philippines14.9. Singapore14.10. South Korea14.11. Taiwan14.12. Thailand14.13. Vietnam15. Europe, Middle East & Africa mRNA Vaccines Market15.1. Introduction15.2. Denmark15.3. Egypt15.4. Finland15.5. France15.6. Germany15.7. Israel15.8. Italy15.9. Netherlands15.10. Nigeria15.11. Norway15.12. Poland15.13. Qatar15.14. Russia15.15. Saudi Arabia15.16. South Africa15.17. Spain15.18. Sweden15.19. Switzerland15.20. Turkey15.21. United Arab Emirates15.22. United Kingdom16. Competitive Landscape16.1. Market Share Analysis, 202416.2. FPNV Positioning Matrix, 202416.3. Competitive Scenario Analysis16.3.1. Pfizer and BioNTech secure FDA approval for tailored Omicron KP.2 COVID-19 vaccine16.3.2. BioNTech and CEPI joined hands to enhance Africa's mRNA vaccine landscape with innovative research and local manufacturing16.3.3. Moderna revealed late-stage trial advancements with progress in the evolution of mRNA vaccine technology16.4. Strategy Analysis & Recommendations For more information about this report visit https://www.researchandmarkets.com/r/azzxne About ResearchAndMarkets.comResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Related News